Sentences with phrase «for olaparib»
As of March 2014, median progression - free survival was 9.2 months for olaparib and 16.7 months for the combination therapy, which is a significant advantage.
https://www.sciencedaily.com/
«The results from this innovative clinical trial are very promising and highlight the potential for olaparib — and other PARP inhibitors — to treat a wide range of cancers.
Not exact matches
Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said, «Our study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.
It could in future allow the PARP inhibitor olaparib to become a standard treatment for advanced prostate cancer, by targeting the drug at the men most likely to benefit, picking up early signs that it might not be working, and monitoring for the later development of resistance.
«Murine study finds potential boost for ovarian cancer drug Olaparib.»
In particular, it has been shown that cells with other HR repair pathway defects, such as BRCA mutations frequently found in breast and ovarian cancer, are sensitive to inhibition of the enzyme PARP, and the PARP inhibitor Olaparib has been approved for treatment of BRCA - mutated ovarian cancers.
«The current options for maintenance therapy in the EU are bevacizumab, which can only be given once and improves progression - free survival by just a few months, and the PARP inhibitor olaparib, which is only approved in patients with a germline BRCA mutation (about 10 - 15 % of ovarian cancer patients).
Olaparib was licensed in December for women with ovarian cancer and inherited BRCA mutations, but the new research suggests it could also benefit men with genomic faults within their tumours.
Of the 16 patients with detectable DNA repair mutations, 14 responded to olaparib — accounting for the large majority of patients who benefited from the drug.
Hence, a total of 90 patients from nine centers were randomly assigned to one of two study arms for the phase II clinical trial: the first taking capsules of olaparib (400 mg twice daily) and the other taking a combination of the two drugs (200 mg olaparib in capsule - form twice daily and 30 mg tablets of cediranib once daily).
«This is the first study to test the promise of a new kind of drug, olaparib, for life - threatening prostate cancer no longer responding to best available treatment.
«The findings of this study are exciting because they support the idea that combining these two targeted oral therapies results in significant activity in ovarian cancer, more so than olaparib alone,» said Joyce Liu, M.D., MPH, the lead investigator and medical oncologist at the Susan F. Smith Center for Women's Cancers at Dana - Farber Cancer Institute, Boston.
They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer.
Three PARPis — olaparib, niraparib, and rucaparib — were recently approved by the FDA for the treatment of breast and ovarian cancers.
They are also looking for «biological signposts» to predict which cancers are most likely to respond to olaparib, which will help doctors identify men who are likely to benefit from the new treatment.
He is currently leading the TOPARP trial, which is finding out whether a drug called olaparib (Lynparza) improves survival for men with advanced prostate cancer that has stopped responding to treatment.
The researchers found that women who took olaparib had a median of 8.4 months before their cancer came back, compared to 4.8 months for those on the placebo.
The OPARATIC trial has paved the way for two additional clinical trials — PARADIGM and PARADIGM - 2 — testing olaparib in combination with radiotherapy and temozolomide in patients with newly diagnosed glioblastoma.